RxDoctor Payments Data

Matthew Dowell, DO

Family Medicine · Edmond, OKNPI 1164457255

Payments from drug & device makers

$11,604in general payments, 2019–2025

Across 853 payments — averaging $13.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Pfizer$933
  • Lilly USA, LLC$865
  • GSK$847
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$11,42498%
  • Education$1812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk127$1,424
AstraZeneca42$1,195
AbbVie(2 entities)86$1,070
Pfizer99$933
Lilly USA, LLC67$865
GSK89$847
Boehringer Ingelheim62$794
Amgen(2 entities)30$463
Abbott19$358
Takeda Pharmaceuticals U.S.A., Inc.22$348
Amarin Pharma, Inc.24$302
Sanofi-aventis U.S. LLC18$261
Merck13$183
Johnson & Johnson11$171
Astellas Pharma US Inc10$171
Bayer9$135
Dexcom, Inc.8$124
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$124
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC7$110
Eisai Inc.6$109
Novartis7$96
Teva Pharmaceuticals USA, Inc.6$88
Sanofi Pasteur Inc.5$86
Otsuka America Pharmaceutical, Inc.4$72
Lundbeck LLC3$72
Madrigal Pharmaceuticals2$64
Currax Pharmaceuticals LLC3$64
Supernus Pharmaceuticals, Inc.4$63
Kowa Pharmaceuticals America, Inc.4$51
Exact Sciences3$50
Ironwood Pharmaceuticals, Inc4$49
Almatica Pharma LLC3$47
Ultragenyx Pharmaceutical Inc.2$46
Biohaven Pharmaceuticals, Inc.3$46
Genentech USA, Inc.2$44
Paratek Pharmaceuticals, Inc.3$42
Nabriva Therapeutics, PLC3$41
Scynexis, Inc.2$38
Kaleo, Inc.2$37
Shire North American Group Inc2$34
E.r. Squibb & Sons, L.L.C.2$33
Shield Therapeutics Inc1$33
Nestle Healthcare Nutrition Inc.2$33
Idorsia Pharmaceuticals US Inc2$29
Ironshore Pharmaceuticals Inc.2$25
Kyowa Kirin, Inc.2$24
Mayne Pharma Commercial LLC1$23
Xeris Pharmaceuticals, Inc.1$21
Edwards Lifesciences1$21
Phathom Pharmaceuticals, Inc.2$21
Corcept Therapeutics1$20
Sumitomo Pharma America, Inc.1$20
Cranial Technologies, Inc1$20
Cequr Corporation1$17
Alk-abello, Inc1$17
Alnylam Pharmaceuticals Inc.1$16
Scilex Pharmaceuticals Inc.1$15
Biogen1$15
Biohaven Pharmaceutical Holding Company Ltd.1$14
Dynavax Technologies Corporation2$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,604 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$153,363
Medicare patients
427
Services billed
3,228

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide98$124,646
JardianceEmpagliflozin74$106,516
MounjaroTirzepatide61$72,461
EliquisApixaban71$60,779
FarxigaDapagliflozin Propanediol37$49,080
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog40$43,963
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog38$26,689
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$22,785
TrulicityDulaglutide12$20,496
Synjardy XrEmpagliflozin/Metformin Hcl11$20,325
MyrbetriqMirabegron31$19,842
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$16,850
Breo ElliptaFluticasone/Vilanterol25$12,960
Tresiba Flextouch U-200Insulin Degludec12$12,899
Aimovig AutoinjectorErenumab-Aooe17$12,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$794$126,84185 claims
Novo NordiskOzempic$1,424$124,64698 claims
Lilly USA, LLCMounjaro, Trulicity$865$92,95773 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,195$68,38475 claims
PfizerEliquis$933$60,77971 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$847$50,80575 claims
Astellas Pharma US IncMyrbetriq$171$19,84231 claims
MerckJanuvia, Dulera$183$10,12423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →